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A unique tool to study malaria immunology and efficacy
of immunization strategies form Controlled Human
Malaria Infections (CHMI) and has proved to be a
reproducible, predictable and safe method of inducing
Plasmodium falciparum (Pf ) malaria. An efficient
method for induction of complete protection in humans
was achieved by us in a CHMI setting by exposing
human subjects to Pf-infected mosquitoes while taking
blood-stage suppressive chloroquine prophylaxis. When
tested in clinical trials, this protocol induced clinical and
parasitological protection against a standard homologous
and heterologous CHMI. In addition, we showed that
CPS-induced protection was long lasting and primarily
mediated by immunity to sporozoite and liver stages
rather than to asexual blood-stages. Cellular responses
to Plasmodium falciparum parasites, in particular inter-
feron-gamma (IFNg) production, CD107a CD4 cells and
Granzyme producing CD8 cells, play an important role
in anti-malarial immunity.
Our approach appears to utilize the Pf parasite’s clini-
cally salient replicative phase of liver stage development to
induce fully protective immune response against sporo-
zoites and liver stages. It opens opportunities to explore
mechanisms of protective immunity, allowing the search
for immune correlates/signatures of protection and clinical
development of a whole sporozoite based vaccine.
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